The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | BCMA-CD38 bispecific CAR-T cells in R/R MM
Yu Hu, MD, PhD, Huazhong University of Science and Technology, Wuhan, China, presents the updated results from a phase 1 dose-climbing trial (ChiCTR1800018143). This trial investigated a bispecific CAR T-cell therapy targeting BCMA and CD38 in patients with relapsed or refractory multiple myeloma (MM), evaluating the safety, efficacy and duration of BM38 T-cells. The initial data provide strong evidence to support the further development of the dual-target CAR-T therapy for relapsed/refractory MM. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
